article thumbnail

The host immune response in COVID-19 and beyond

pharmaphorum

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. One of these involves listening to what the body’s own immune system can tell us. This is made possible using ‘Advanced Host Immune Response Technologies’.

article thumbnail

Health Innovators: PureTech Health’s Daphne Zohar

pharmaphorum

They discuss the publicly-listed biotech’s pipeline projects and focus on the BIG (brain-immune-gut) axis as well as PureTech’s interest in digital therapeutics. Prior to this, he founded pharmaphorum in 2009, which was acquired by Healthware Group in June 2020.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

The vaccination of patients with AN1792 led to the activation of their immune systems, which started producing endogenous anti-Abeta antibodies. Therefore, active immunotherapy to trigger the immune system to produce sustained levels of endogenous antibodies has now become far more attractive.

article thumbnail

Acetaminophen interactions to avoid

The Checkup by Singlecare

Acetaminophen may also blunt the effects of other medications that impact the immune system, including some medicines used to manage cancer diagnoses and even the immune response following vaccinations. If alternatives to acetaminophen can be employed, they should be recommended. Warfarin and acetaminophen interaction , Blood (2011).

article thumbnail

Low Dose Naltrexone and Hashimoto’s

The Thyroid Pharmacist

However, low doses of this medication (hence, low dose naltrexone or LDN), have been found to modulate the immune system and have shown promise in improving cases of autoimmune disease. These include Crohn’s, MS, and Hashimoto’s, as well as other immune system-related conditions such as cancer and HIV/AIDS. Doses of 1.5-4.5

article thumbnail

Tackling diabetes & ALS with cell therapy

pharmaphorum

Using micro-encapsulation technology, integrated within IsletRx, the islet cells are protected from attack by the host immune system. The product in development, IsletRx, is clinical grade pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels.

article thumbnail

Merck Reports the US FDA Acceptance of sBLA for Keytruda (pembrolizumab) to Treat Advanced or Unresectable Biliary Tract Cancer

PharmaShots

OS rate (52% & 24.9%

FDA 40